Monopar Therapeutics (MNPR) Equity Ratio (2016 - 2020)
Historic Equity Ratio for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to 0.96.
- Monopar Therapeutics' Equity Ratio rose 641.53% to 0.96 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.96, marking a year-over-year increase of 641.53%. This contributed to the annual value of 0.95 for FY2019, which is 3.83% up from last year.
- Per Monopar Therapeutics' latest filing, its Equity Ratio stood at 0.96 for Q3 2020, which was up 641.53% from 0.95 recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Equity Ratio registered a high of 0.98 during Q4 2016, and its lowest value of 0.91 during Q3 2019.
- Moreover, its 5-year median value for Equity Ratio was 0.96 (2018), whereas its average is 0.95.
- Per our database at Business Quant, Monopar Therapeutics' Equity Ratio crashed by 614.69% in 2019 and then soared by 641.53% in 2020.
- Quarter analysis of 5 years shows Monopar Therapeutics' Equity Ratio stood at 0.98 in 2016, then fell by 0.93% to 0.97 in 2017, then dropped by 2.39% to 0.95 in 2018, then increased by 0.04% to 0.95 in 2019, then increased by 1.87% to 0.96 in 2020.
- Its Equity Ratio stands at 0.96 for Q3 2020, versus 0.95 for Q2 2020 and 0.97 for Q1 2020.